Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 5, September-October, p. 689–694

Publication type: review article

Language: English

The Genetic Background of Crohn’s Disease – Basic Genetic Definitions and the Gene CARD15

Genetyczne podłoże choroby Leśniowskiego−Crohna – podstawowe pojęcia z zakresu genetyki i gen CARD15

Anna Sadakierska−Chudy1,, Katarzyna Neubauer2,, Elżbieta Poniewierka2,

1 Molecular Techniques Unit, Department of Forensic Medicine, Silesian Piasts University of Medicine in Wrocław, Poland

2 Department of Gastroenterology and Hepatology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

The complicated etiopathogenesis of Crohn’s disease includes a genetic background. Many epidemiological studies show geographical, racial, and ethnic differences in disease prevalence as well as familial occurrence. A genetic background is currently confirmed by molecular studies. The first gene identified as a “susceptibility” gene of Crohn’s disease was NOD2/CARD15. This paper explains the basic genetic definitions and the role of the CARD15 gene.

Streszczenie

W wieloczynnikowej etiopatogenezie choroby Leśniowskiego−Crohna uwzględnia się podłoże genetyczne. Przemawiają za tym obserwacje epidemiologiczne stwierdzające różnice geograficzne, rasowe i etniczne w częstości występowania choroby oraz jej występowanie rodzinne. Obecnie podłoże genetyczne choroby znajduje także potwierdzenie na płaszczyźnie badań molekularnych. Pierwszym zidentyfikowanym genem „podatności” na chorobę Leśniowskiego−Crohna był gen CARD15. Artykuł przybliża podstawowe pojęcia z zakresu genetyki oraz rolę genu CARD15.

Key words

Crohn’s disease, CARD15

Słowa kluczowe

choroba Leśniowskiego−Crohna, CARD15

References (24)

  1. Błachut K, Krzystek−Korpacka M, Matusiewicz M, Petryszyn P, Kustrzeba−Wójcicka I, Banaś T, Paradowski L: Angiogenic factors VEGF−A, VEGF−C and midkine are elevated in flare and remission of ulcerative colitis and Chrohn’s disease. J Crohn’s Colitis Suppl 2007, 29, P100, Abstracts of ECCO Congress. Innsbruck, Austria, 1–3 March 2007.
  2. Paradowski L, Neubauer K, Kollbek P: Epidemiologia nieswoistych zapaleń jelit, skala problemu. Med Dypl 2007, suppl. 05/07, 33–37.
  3. Shivananda S, Leonard−Jones J, Logan R, the EC−IBD Study Group: Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC−IBD). Gut 1996, 39, 690–697.
  4. Halfvarson J, Jess T, Magnusom A, Montgomery SM, Orholm M, Tysk C, Binder V, Järnerot G: Environmental factors in inflammatory bowel disease: a co−twin control study of a Swedish−Danish twin population. Inflamm Bowel Dis 2006, 12, 925–933.
  5. Bridger S, Lee JCW, Bjarnason I, Leonard Jones JE: In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non−smokers develop ulcerative colitis. Gut 2002, 51, 21–25.
  6. Russell RK, Satsangi J: IBD: a family affair. Best Pract Res Clin Gastroenterol 2004, 18, 525–539.
  7. Csillag C, Nielsen OH, Vainer B, Olsen J, Dieckgraefe BK, Hendel J, Vind I, Dupuy C, Nielsen FC, Borup R: Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet−derived 1 alpha in Crohn’s disease. Scand J Gastroenterol 2007, 42, 454–463.
  8. Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR: NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology 2007, 132, 576–586.
  9. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S: Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53, 685–693.
  10. Hugot JP, Laurent−Puig P, Gower−Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti−Pellie C, Weissenbach J, Mathew CG, Lennard−Jones JE, Cortot A, Colombel JF, Thomas G: Mapping of susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996, 379, 821–823.
  11. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morgain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent−Puig P, Gower−Rousseau C, Macry J, Colombel JF, Shbatou M, Thomas G: Association of NOD2 leucine−rich repeat variants with susceptibility to Crohn’s disease. Nature 2001, 411, 599–603.
  12. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Morgan T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001, 411, 603–606.
  13. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard−Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001, 357, 1925–1928.
  14. Russell RK, Nimmo ER, Satangi J: Molecular genetics of Crohn’s disease. Curr Opin Gen Develop 2004, 14, 264–270.
  15. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O’Morain C, Ruiz−Ochoa V, Odes S, Binder V, Munkholm P, Moum B, Stockbrügger R, Langholz E, European Collaborative Study Group on Inflammantory Bowel Disease: The prevalence of genetic and serologic markers in an unselected European population−based cohort of IBD patients. Inflamm Bowel Dis 2007, 13, 24–32.
  16. Hsiao CH, Wei SC, Wong JM, Lai HS, Chang MH, Ni YH: Pediatric Crohn's disease: clinical and genetic characteristics in Taiwan. J Pediatr Gastroenterol Nutr 2007, 44, 342–346.
  17. Aldhous MC, Nimmo ER, Satsangi J: NOD2/CARD15 and Paneth cell: another piece in the genetic jigsaw of inflammatory bowel disease. Gut 2002, 52, 1533–1535.
  18. Zouali H, Lesage S, Merlin F, Cézard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull M, Christensen S, Finkel Y, Modigliani R, Gower−Rousseau C, Macry J, Chamaillard M, Thomas G, Hugot JP: EPIMAD group, EPWG−IBD group, GETAID Group. CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003, 52, 71–74.
  19. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G: Nod2, a Nod2/Apaf−1 family member that is restricted to monocytes and activates NF−κB. J Biol Chem 2001, 276, 4812–4818.
  20. Inohara N, Ogura Y, Numez G: Nods: a family of cytosolic proteins that regulate the response to pathogens. Curr Opin Microbiol 2002, 5, 76–80.
  21. Van der Linde K, Boor PP, Houwing−Duistermaat JJ, Crusius BJ, Wilson PJ, Kuipers EJ, de Rooij FW: CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. Eur J Gastroenterol Hepatol 2007, 19, 449–459.
  22. Helio T, Halme L, Lappalainen M: CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003, 52, 552–557.
  23. Dobrowolska−Zachwieja A, Kaczmarek M, Hoppe−Gołębiewska, Kalak R, Słomski R, Linke K: Wpływ wariantu mutacji NOD2/CARD15 na występowanie objawów spoza przewodu pokarmowego u chorych z choroba Leśniowskiego−Crohna w populacji polskiej. Now Lek 2004, 73, 337–348.
  24. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID, Satsangi J: The contribution of OCTN1/2 variants within the IBD6 locus to disease susceptibility and severity in Crohn’s disease. Gastroenterology 2005, 129, 1854–1864.
© Wroclaw Medical University